CMS Finalizes Mandatory GLOBE Rebate Model for Medicare Part B Drugs
CMS has finalized the GLOBE Medicare rebate model, a mandatory program applying additional rebates to certain Part B drugs; reporting suggests only a limited set of products will be affected.
On October 2, 2026, the Centers for Medicare & Medicaid Services finalized the Global Benchmark for Efficient Drug Pricing (GLOBE) Model, a mandatory Medicare demonstration that assesses additional rebates on drugs payable under Part B. Because the model is mandatory rather than voluntary, covered manufacturers cannot decline participation, and rebate obligations flow through existing Part B payment mechanics rather than a voluntary contract structure.
The reported scope is narrow: the analysis indicates only a handful of Part B drugs will be affected, which limits near-term pricing exposure for most large-cap and mid-cap pharmaceutical portfolios. Even so, counsel should not dismiss it. Part B rebate economics interact with ASP reporting, Medicaid and 340B obligations, distribution contracting with specialty and physician-office channels, and any existing risk-sharing or value-based agreements. A manufacturer in scope will need to model how additional GLOBE rebates alter net pricing per unit, alter channel incentives, and potentially compress launch expectations for a product early in its lifecycle.
Practical next steps: confirm which products and measurement periods are covered (the source does not specify them), reassess contractual rebate pass-through language in Part B distribution agreements, and track CMS sub-regulatory guidance and any comment-based changes. Participation mechanics, timelines, and the precise rebate calculation method are not detailed in the available reporting and should be verified against the final rule text.